四环医药(00460.HK)：惠升生物研发的羟苯磺酸钙胶囊获准上市

阿斯达克财经06-27

四环医药(00460.HK) 公布，公司旗下非全资附属公司惠升生物研发的羟苯磺酸钙胶囊已获内地国家药监局颁发的药品注册证书，可视同通过仿制药质量和疗效一致性评价。羟苯磺酸钙胶囊今次获批用于微血管病的治疗，如糖尿病性微血管病变-视网膜病及肾小球硬化症，微血管损伤等。(vc/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-26 16:25。)AASTOCKS新闻

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2446374593?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220413154448549_s.jpg","is_english":false,"pubTime":"2024-06-27 12:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2446374593","market":"other","top_or_hot":-1,"title":"四环医药(00460.HK)： 惠升生物研发的羟苯磺酸钙胶囊获准上市","media":"阿斯达克财经","content":"<div>\n<p>四环医药(00460.HK) 公布，公司旗下非全资附属公司惠升生物研发的羟苯磺酸钙胶囊已获内地国家药监局颁发的药品注册证书，可视同通过仿制药质量和疗效一致性评价。羟苯磺酸钙胶囊今次获批用于微血管病的治疗，如糖尿病性微血管病变-视网膜病及肾小球硬化症，微血管损伤等。(vc/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-26 16:25。)AASTOCKS新闻</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1359661/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>四环医药(00460.HK)： 惠升生物研发的羟苯磺酸钙胶囊获准上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n四环医药(00460.HK)： 惠升生物研发的羟苯磺酸钙胶囊获准上市\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-27 12:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1359661/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>四环医药(00460.HK) 公布，公司旗下非全资附属公司惠升生物研发的羟苯磺酸钙胶囊已获内地国家药监局颁发的药品注册证书，可视同通过仿制药质量和疗效一致性评价。羟苯磺酸钙胶囊今次获批用于微血管病的治疗，如糖尿病性微血管病变-视网膜病及肾小球硬化症，微血管损伤等。(vc/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-26 16:25。)AASTOCKS新闻</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1359661/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1600","symbol_name":"工业大麻","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1359661/latest-news/AAFN","article_id":"2446374593","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220413154448549_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446374593","pubTimestamp":1719462120,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"四环医药(00460.HK) 公布，公司旗下非全资附属公司惠升生物研发的羟苯磺酸钙胶囊已获内地国家药监局颁发的药品注册证书，可视同通过仿制药质量和疗效一致性评价。羟苯磺酸钙胶囊今次获批用于微血管病的治疗，如糖尿病性微血管病变-视网膜病及肾小球硬化症，微血管损伤等。(vc/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-26 16:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1600":"工业大麻","BK1191":"制药","BK1515":"抗疫概念","BK1593":"医美概念股","00460":"四环医药"},"translate_title":"Sihuan Pharmaceutical (00460. HK): Calcium dobesilate capsules developed by Huisheng Biotech approved for marketing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1},"content_text":"四环医药(00460.HK) 公布，公司旗下非全资附属公司惠升生物研发的羟苯磺酸钙胶囊已获内地国家药监局颁发的药品注册证书，可视同通过仿制药质量和疗效一致性评价。羟苯磺酸钙胶囊今次获批用于微血管病的治疗，如糖尿病性微血管病变-视网膜病及肾小球硬化症，微血管损伤等。(vc/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-26 16:25。)AASTOCKS新闻","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446374593"}

四环医药(00460.HK)： 惠升生物研发的羟苯磺酸钙胶囊获准上市

精彩评论

四环医药(00460.HK)：惠升生物研发的羟苯磺酸钙胶囊获准上市